NOVA Expands JINKO Platform Pact with Janssen

Novadiscovery (NOVA), a health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, has expanded its collaboration with Janssen, initially entered in 2020.
 
NOVA is now applying its collaborative clinical trial simulation platform, JINKO, to expand the existing lung cancer model to support Janssen market access and global medical affairs strategies.
 
This agreement follows an agreement which saw NOVA use publicly-available knowledge and data to create a bedrock predictive disease model for lung adenocarcinoma which was then validated using an independent database from Paz-Ares study (Lux-Lung7 cohort) and benchmarked using the Bayesian model developed by Nagase et al. in 2020.
 
The companies will now work together to use the JINKO platform to add layers of biological complexity to the initial disease model and then run in silico trial simulations.
 
“The initial proof-of-concept success means Janssen’s leap-of-faith into in silico has been justified, which makes us very proud,” said François-Henri Boissel, CEO. “We are looking forward to deploying JINKO and developing disease models that will provide real insight for drug makers, streamlining clinical development and getting life-saving treatments to patients faster.”
 
“Janssen is dedicated to employing the most advanced and innovative technologies to ensure new treatments progress through clinical development as efficiently as possible so patients benefit from approved medicines without unnecessary delay. NOVA’s generated proof-of-concept of its predictive disease models through our preliminary work over the past year and we look forward to continuing our ground-breaking work,” said Véronique Schmitt, director of Market Access, Governmental Affairs & Early Products Development – Janssen France.